The overarching goal of the Oregon ADC (OADC) is twofold: (1) to focus on early detection of change in order to define mechanisms supporting healthy brain aging and the transition to MCI and early dementia, and (2) to facilitate developing effective therapies to prevent or limit these transitions. To achieve these objectives, six cores are organized to catalyze and sustain innovative research and discovery in Alzheimer Disease (AD) and related disorders through an organizational infrastructure that supports a rich collaborative environment composed of leading edge technologies and methods, multi-disciplinary scientists, empowered research volunteers, and an inspired community of lay and professional stakeholders. The OADC provides the necessary materials to support research through well-characterized research participants, biological specimens, brain tissue, data provision and analytics. The OADC focuses on specific areas of emphasis: (1) Preclinical dementia and activity of disease emphasizing the oldest old; (2) Markers of meaningful change captured through studies of peripheral biomarkers, neuroimaging and continuous in-home behavioral monitoring; (3) Neuropathology of brain aging and late life dementia; (4) Novel testing of novel treatments; and (5) Improving education and sharing knowledge about dementia. To attain these goals and objectives, the OADC Specific Aims are to: 1. Catalyze and sustain innovative research and discovery in AD and related disorders through an organizational infrastructure supporting a rich collaborative environment composed of leading edge technologies and methods, multi-disciplinary scientists, empowered research volunteers, and an inspired community of lay and professional stakeholders. 2. Focus the innovation and discovery infrastructure of the center toward specific areas of emphasis: (1) Preclinical dementia and activity of disease emphasizing the oldest old; (2) Markers of meaningful change captured through studies of peripheral biomarkers, neuroimaging and continuous in-home behavioral monitoring; (3) Neuropathology of brain aging and late life dementia; (4) Novel testing of novel treatments; and (5) Improving education and knowledge about dementia. 3. Provide the necessary materials to support the science through well-characterized research participants, biological specimens, brain tissue, data provision and analytics. 4. Contribute to the national research commons relevant to AD and related disorders. 5. Provide venues and mechanisms for education and training of new scientists, as well as educating and informing key stakeholders such as clinicians, patients and diverse family members to address the challenges of dementia.

Public Health Relevance

Overall The Oregon Alzheimer's Disease Center infrastructure creates a unique environment for research and discovery of new insights into healthy brain aging, transitions to Alzheimer's, and for treatment and management of cognitive decline. This is facilitated by state-of the art clinical, biochemical, technological and statisticl tools, subject and tissue resources, and data widely shared for maximum impact with the scientific community and appropriately translated to families and other key stakeholders.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Center Core Grants (P30)
Project #
2P30AG008017-26
Application #
8848722
Study Section
Special Emphasis Panel (ZAG1-ZIJ-7 (J1))
Program Officer
Silverberg, Nina B
Project Start
1997-01-01
Project End
2020-03-31
Budget Start
2015-04-15
Budget End
2016-03-31
Support Year
26
Fiscal Year
2015
Total Cost
$1,540,000
Indirect Cost
$540,000
Name
Oregon Health and Science University
Department
Neurology
Type
Schools of Medicine
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Agogo, George O; Ramsey, Christine M; Gnjidic, Danijela et al. (2018) Longitudinal associations between different dementia diagnoses and medication use jointly accounting for dropout. Int Psychogeriatr 30:1477-1487
Wardzala, Casia; Murchison, Charles; Loftis, Jennifer M et al. (2018) Sex differences in the association of alcohol with cognitive decline and brain pathology in a cohort of octogenarians. Psychopharmacology (Berl) 235:761-770
Alosco, Michael L; Sugarman, Michael A; Besser, Lilah M et al. (2018) A Clinicopathological Investigation of White Matter Hyperintensities and Alzheimer's Disease Neuropathology. J Alzheimers Dis 63:1347-1360
Brent, Robert J (2018) Estimating the monetary benefits of medicare eligibility for reducing the symptoms of dementia. Appl Econ 50:6327-6340
Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872
Besser, Lilah; Kukull, Walter; Knopman, David S et al. (2018) Version 3 of the National Alzheimer's Coordinating Center's Uniform Data Set. Alzheimer Dis Assoc Disord 32:351-358
Tse, Kai-Hei; Cheng, Aifang; Ma, Fulin et al. (2018) DNA damage-associated oligodendrocyte degeneration precedes amyloid pathology and contributes to Alzheimer's disease and dementia. Alzheimers Dement 14:664-679
Crum, Jana; Wilson, Jeffrey; Sabbagh, Marwan (2018) Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer's dementia? Alzheimers Res Ther 10:104
Schaffert, Jeff; LoBue, Christian; White, Charles L et al. (2018) Traumatic brain injury history is associated with an earlier age of dementia onset in autopsy-confirmed Alzheimer's disease. Neuropsychology 32:410-416
Burke, Shanna L; Cadet, Tamara; Maddux, Marlaina (2018) Chronic Health Illnesses as Predictors of Mild Cognitive Impairment Among African American Older Adults. J Natl Med Assoc 110:314-325

Showing the most recent 10 out of 482 publications